Elevai Labs, Inc. (NASDAQ:ELAB) Sees Large Drop in Short Interest

Elevai Labs, Inc. (NASDAQ:ELAB) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 19,400 shares, a decline of 89.6% from the February 13th total of 185,700 shares. Based on an average daily trading volume, of 302,600 shares, the short-interest ratio is presently 0.1 days. Approximately 0.6% of the company’s shares are sold short.

Elevai Labs Trading Down 12.7 %

Shares of Elevai Labs stock traded down $0.60 during trading hours on Wednesday, hitting $4.11. The company’s stock had a trading volume of 75,972 shares, compared to its average volume of 311,430. The business has a fifty day moving average of $12.36 and a 200 day moving average of $97.62. Elevai Labs has a 1-year low of $3.88 and a 1-year high of $1,134.00. The company has a quick ratio of 3.40, a current ratio of 3.86 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $2.38 million, a PE ratio of -0.07 and a beta of -2.93.

Elevai Labs Company Profile

Elevai Labs, Inc, a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc and changed its name to Elevai Labs, Inc in December 2021.